MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-60.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MNMD vs ATAI
Revenue, margins, valuation, and 5-year total return — side by side.
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$1.00B
5Y Perf.-80.9%
MNMD vs ATAI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNMD | ATAI |
|---|---|---|
| Industry | Biotechnology | Medical - Pharmaceuticals |
| Market Cap | $2.04B | $1.00B |
| Revenue (TTM) | $0.00 | $3M |
| Net Income (TTM) | $-184M | $-154M |
| Gross Margin | — | -259.1% |
| Operating Margin | — | -34.6% |
| Total Debt | $0.00 | $25M |
| Cash & Equiv. | $258M | $18M |
MNMD vs ATAI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNMD
ATAI
| Stock | Jun 21 | Apr 26 | Return |
|---|---|---|---|
| Mind Medicine (Mind… (MNMD) | 100 | 40.0 | -60.0% |
| Atai Beckley N.V (ATAI) | 100 | 19.1 | -80.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNMD vs ATAI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNMD and ATAI are tied at the top with 2 categories each — the right choice depends on your priorities. Atai Beckley N.V is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 5.1% 10Y total return vs ATAI's -46.9%
- +227.9% vs ATAI's +202.2%
- -41.8% ROA vs ATAI's -64.3%, ROIC -389.5% vs -45.0%
Best for: long-term compounding
ATAI
Atai Beckley N.V
The Income Pick
ATAI is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.48
- Rev growth -1.9%, EPS growth -272.0%, 3Y rev CAGR -75.3%
- Lower volatility, beta 1.48, Low D/E 21.2%, current ratio 3.21x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATAI | -1.9% revenue growth vs MNMD's -64.9% |
| Stability / Safety | ATAI | Beta 1.48 vs MNMD's 1.68 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNMD | +227.9% vs ATAI's +202.2% |
| Efficiency (ROA) | MNMD | -41.8% ROA vs ATAI's -64.3%, ROIC -389.5% vs -45.0% |
MNMD vs ATAI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
MNMD vs ATAI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGATAI
ATAIAtai Beckley N.V
0leads
MNMDMind Medicine (MindMe…
4leads
6 Total Categories
CATEGORYLEADERvs ATAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MNMD1/1
Valuation MetricsMultiples, price ratios, and targets
MNMD2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNMD6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MNMD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATAI and MNMD operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | MNMDMind Medicine (Mi… | ATAIAtai Beckley N.V |
|---|---|---|
| RevenueTrailing 12 months | $0 | $3M |
| EBITDAEarnings before interest/tax | -$156M | -$103M |
| Net IncomeAfter-tax profit | -$184M | -$154M |
| Free Cash FlowCash after capex | -$161M | -$90M |
| Gross MarginGross profit ÷ Revenue | — | -2.6% |
| Operating MarginEBIT ÷ Revenue | — | -34.6% |
| Net MarginNet income ÷ Revenue | — | -51.1% |
| FCF MarginFCF ÷ Revenue | — | -29.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.0% | -75.0% |
MNMD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
MNMD leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | MNMDMind Medicine (Mi… | ATAIAtai Beckley N.V |
|---|---|---|
| Market CapShares × price | $2.0B | $1.0B |
| Enterprise ValueMkt cap + debt − cash | $1.8B | $1.0B |
| Trailing P/EPrice ÷ TTM EPS | -10.04x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3255.27x |
| Price / BookPrice ÷ Book value/share | 5.56x | 5.73x |
| Price / FCFMarket cap ÷ FCF | — | — |
MNMD leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
MNMD leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
MNMD delivers a -55.3% return on equity — every $100 of shareholder capital generates $-55 in annual profit, vs $-96 for ATAI. On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs ATAI's 2/9, reflecting mixed financial health.
| Metric | MNMDMind Medicine (Mi… | ATAIAtai Beckley N.V |
|---|---|---|
| ROE (TTM)Return on equity | -55.3% | -96.4% |
| ROA (TTM)Return on assets | -41.8% | -64.3% |
| ROICReturn on invested capital | -3.9% | -45.0% |
| ROCEReturn on capital employed | -52.2% | -50.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.21x |
| Net DebtTotal debt minus cash | -$258M | $7M |
| Cash & Equiv.Liquid assets | $258M | $18M |
| Total DebtShort + long-term debt | $0 | $25M |
| Interest CoverageEBIT ÷ Interest expense | -14.63x | -68.93x |
MNMD leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,045 today (with dividends reinvested), compared to $2,097 for ATAI. Over the past 12 months, MNMD leads with a +227.9% total return vs ATAI's +202.2%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs ATAI's 27.5% — a key indicator of consistent wealth creation.
| Metric | MNMDMind Medicine (Mi… | ATAIAtai Beckley N.V |
|---|---|---|
| YTD ReturnYear-to-date | +51.7% | +7.8% |
| 1-Year ReturnPast 12 months | +227.9% | +202.2% |
| 3-Year ReturnCumulative with dividends | +510.3% | +107.5% |
| 5-Year ReturnCumulative with dividends | -59.6% | -79.0% |
| 10-Year ReturnCumulative with dividends | +512.1% | -46.9% |
| CAGR (3Y)Annualised 3-year return | +82.7% | +27.5% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNMD and ATAI each lead in 1 of 2 comparable metrics.
Risk & Volatility
ATAI is the less volatile stock with a 1.48 beta — it tends to amplify market swings less than MNMD's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs ATAI's 61.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MNMDMind Medicine (Mi… | ATAIAtai Beckley N.V |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 1.48x |
| 52-Week HighHighest price in past year | $21.09 | $6.75 |
| 52-Week LowLowest price in past year | $6.03 | $1.29 |
| % of 52W HighCurrent price vs 52-week peak | +98.1% | +61.8% |
| RSI (14)Momentum oscillator 0–100 | 64.9 | 46.6 |
| Avg Volume (50D)Average daily shares traded | 806K | 6.0M |
Evenly matched — MNMD and ATAI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MNMD as "Buy" and ATAI as "Buy". Consensus price targets imply 187.8% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).
| Metric | MNMDMind Medicine (Mi… | ATAIAtai Beckley N.V |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $20.00 | $12.00 |
| # AnalystsCovering analysts | 1 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 4 of 6 categories
Loading custom metrics...
MNMD vs ATAI: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MNMD or ATAI a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MNMD or ATAI?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -59. 6%, compared to -79. 0% for Atai Beckley N. V (ATAI). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus ATAI's -46. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MNMD or ATAI?
By beta (market sensitivity over 5 years), Atai Beckley N.
V (ATAI) is the lower-risk stock at 1. 48β versus Mind Medicine (MindMed) Inc. 's 1. 68β — meaning MNMD is approximately 14% more volatile than ATAI relative to the S&P 500.
04Which is growing faster — MNMD or ATAI?
On earnings-per-share growth, the picture is similar: Atai Beckley N.
V grew EPS -272. 0% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MNMD or ATAI?
Mind Medicine (MindMed) Inc.
(MNMD) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MNMD or ATAI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MNMD or ATAI better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Both have compounded well over 10 years (MNMD: +512. 1%, ATAI: -46. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MNMD and ATAI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.